JournalScan
| The first 150 words of the full text of this article appear below. |
ISCHAEMIC HEART DISEASE
Dual antiplatelet treatment with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. The authors randomly assigned 15 603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75–162 mg per day) or placebo plus low-dose aspirin, and followed them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction (MI), stroke, or death from cardiovascular causes. The rate of the primary efficacy end point was 6.8% with clopidogrel plus aspirin and 7.3% with placebo plus aspirin (relative risk (RR) 0.93, 95% confidence interval (CI) 0.83 to 1.05; p = 0.22). The respective rate of the principal secondary efficacy end point, which included hospitalisations for ischaemic events, was 16.7% and 17.9% (RR 0.92, 95% CI 0.86 to 0.995; p =
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
